Skip to content

Milestone Monday: Who Let The Biotechs In?

Windward Bio raised $225m in a traditional IPO, while Mentari’s reverse merger brought in $490m and Brains Bioceutical chose a SPAC, showing biotechs are finding many ways to reach public money.

A picture showing scenes at a music concert with people gathered in front of a stage with bright lights and smoke
Once you’re inside, nobody asks how you got past the gate. Photo by Yvette de Wit / Unsplash

If you’ve ever tried to get into a busy party without being on the guest list, you know the drill. The front door is the obvious way in, but there is a queue and a bouncer intent on keeping people out. A lucky few get a friend who’s already inside to hold the door open for them, while others try to slip in through the back door.

Biotech had all those last week. Windward Bio walked in through the front door with a $225m IPO, the 30th US biopharma listing of 2026, while Rezera reached the front of the queue, it still hasn't made its way inside.

Mentari raised $490m by slipping in through the back door of a reverse merger, Brains Bioceutical found a back door of its own in a SPAC, and Pfizer got Blackstone to hold the door for its monthly GLP-1.

Walking In Through The Front Door

Windward, based in Basel, Switzerland, sold 10.29 million shares at $17 a pop, at the midpoint of its $16-$18 range, raising $175m. Sanofi added $50m in a concurrent private placement, taking the total to $225m. Sanofi Ventures had previously joined Windward’s $165m crossover round in May.

The IPO proceeds will fund two late-stage asthma trials of WIN378, an anti-TSLP antibody dosed twice a year, compared with monthly dosing for Amgen and AstraZeneca’s Tezspire. They are POLARIS-1, a Phase II/III study, and POLARIS-2, a Phase III study due to start in the first quarter of 2027. Windward’s second drug, WIN027, a TSLP/IL-13 bispecific, is due to start a Phase IIb trial in COPD and a Phase II trial in atopic dermatitis in the first half of 2027.